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Since Italian liver allocation policy was last revised (in
2012), relevant critical issues and conceptual advances
have emerged, calling for significant improvements.We
report the results of a national consensus conference
process, promoted by the Italian College of Liver
Transplant Surgeons (for the Italian Society for Organ
Transplantation) and the Italian Association for the
Study of the Liver, to review the best indicators for
orientingorganallocationpoliciesbasedonprinciplesof
urgency, utility, and transplant benefit in the light
of current scientific evidence. MELD exceptions and
hepatocellular carcinoma were analyzed to construct a
transplantation priority algorithm, given the inequity of
a purely MELD-based system for governing organ
allocation. Working groups of transplant surgeons and
hepatologists prepared a list of statements for each
topic, scoring their quality of evidence and strength
of recommendation using the Centers for Disease
Control grading system. A jury of Italian transplant
surgeons, hepatologists, intensivists, infectious disease
specialists, epidemiologists, representativesofpatients’
associations and organ-sharing organizations, trans-
plant coordinators, and ethicists voted on and validated
the proposed statements. After carefully reviewing the
statements, a critical proposal for revising Italy’s current
liver allocation policywas prepared jointly by transplant
surgeons and hepatologists.
Abbreviations: AISF, Italian Association for the Study
of the Liver; HCC, hepatocellular carcinoma; LT, liver
transplantation; MELD, model for end-stage liver
disease; NTC, National Transplantation Center;
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TNT, nontransplantable; TT, transplantable; UNOS,
United Network for Organ Sharing
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Introduction
Allocation systems relying mainly on the principle of
urgency, like those prioritizing patients with higher MELD
scores, have several inherent weaknesses because MELD
score measures severity of disease, but often fails to
predict outcome after liver transplantation (LT) (1). MELD
scores also cannot gauge the severity of several diseases
currently considered ‘‘MELD exceptions,’’ or of hepatocel-
lular carcinoma (HCC) in patients with compensated
cirrhosis (2). In a recent prospective Italian series of LT,
MELD was unable to describe the disease’s severity in
almost 50% of the cases (3).
Assessments designed to assure equitable access to LT
should therefore distinguish between patients with decom-
pensated cirrhosis (when the urgency principle based on
MELD score is applicable) and patients with MELD
exceptions or HCC and compensated cirrhosis. The latter
can be considered prototypic MELD exceptions because a
MELD-based system fails to capture their risk of dropout
due to tumor progression or liver-related complicationswith
no bearing on MELD score (4). The appropriate selection of
candidates with or without HCC for LT, and their priority on
the waiting list, therefore cannot be achieved with models
based on urgency alone (Appendix 1). The principles of
urgency and utility must be balanced and integrated with
transplant benefit (5).
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Several proposed models focusing on urgency, utility or
benefit principles, or combinations thereof, involve adjust-
ing scores, matching donors and recipients, and other
optimizations, assuming that access to LT is not the only
goal; delisting criteria, long-term transplantation outcomes,
and organ availability must be considered, as well as the
expected results of alternative therapies (6–12). The issue’s
complexity, the number of variables and different medical,
social and political figures involved, and the huge differ-
ences in local and regional scenarios have all contributed to
hindering the development of a consensual allocation/
priority system that considers all the above elements.
Italy’s organ transplantation network is governed by the
National Transplantation Center (CNT). It has 21 LT centers
in 13 regions, grouped into 2 macro areas (central-northern
and central-southern Italy). Since the CNT’s inception, its
liver allocation policies have seen several modifications.
The current policy stems from a revision in 2012 designed
to expand macro area and nationwide organ sharing
according to urgency principles. Organs are shared:
nationwide for the most severely ill candidates classifiable
as UNOS Status 1 (super-urgent); by macro area for
patients with MELD #30; and regionally for patients with
MELD$29 (theminimum score for listing a patient for LT is
15) (10). The arbitrary cutoff at 30 was chosen because
patients with MELD >30 at transplantation represented
the highest decile (10%) of patients transplanted in Italy in
the previous year (2011). With this allocation system,
policies at local levelmaybe heterogeneous,with a potential
imbalance among different liver disease etiologies.
Given these areas of contention, a national consensus
conference process was arranged with the contribution of
all interested parties to enable a broad discussion of these
important aspects of Italy’s liver allocation policies. The
aims of the multistep consensus conference were to
% identify the best urgency, utility, and benefit indicators to
consider for organ allocation purposes (first step);
% identify MELD exceptions, and choose the best indica-
tors to consider for organ allocation in such cases
(second step); and
% prepare a working proposal for revising the current
allocation system (third step).
A further consensus conference on the ethical issues of LT
was held within the same time frame (the results of which
will be presented elsewhere).
Liver allocation to pediatric patients was not considered
because they are the object of a separate national list and
different policy.
The present report outlines the group discussions, and the
resulting working proposal for revising Italy’s current
allocation policy for LT. The consensus conference method
and results could serve as amodel and stimulate the debate
for future improvements to liver allocation systems
adopted in Italy and elsewhere.
Methods
The consensus conference was promoted by the Italian College of Liver
Transplant Surgeons (for the Italian Society forOrgan Transplantation [SITO])
and the Italian Association for the Study of the Liver (AISF). The promoters
appointed a Scientific Board of Experts with two coordinators from SITO and
AISF, two liver transplant surgeons, and two transplant hepatologists, all
recognized as leading experts in their field.
The topics of the first and second steps were discussed at separate
consensus conferences in 2012 and 2013. For each topic, the promoters and
Scientific Board identified working groups of surgeons and hepatologists
chosen for their expertise and publications on liver disease and transplanta-
tion. The working groups independently conducted systematic literature
reviews, then met for morning background presentations and afternoon
discussions, drafting definitions and statements graded according to the
CDC system (13). Appendix 2 contains a flowchart summarizing the key
steps in this preparatory phase.
The statements were put to the vote of a jury of transplant surgeons,
hepatologists, intensivists, infectious disease specialists, epidemiologists,
representatives of patients’ associations, representatives of organ-sharing
organizations, transplant coordinators, and ethicists. None of the jury
members had been involved in choosing the topics or preparing the
statements. Eachworking group’s chairman presented their statements in a
format that involved first asking a question, then giving one ormore answers
based on a statement’s CDC-graded quality of evidence and strength of
recommendation. A general discussion was held to refine and revise the
statements, then each statement was voted on, taking the jury’s votes as
valid and the audience’s votes for reference.
After further careful review of the approved statements, a group of expert
liver transplant surgeons and transplant hepatologists prepared the
operative scheme described here, which will be presented to all parties
involved in LT at a meeting scheduled for mid-2015.
Consensus Conference Outcomes
The statements approved at the conference on the
definition of the principles of utility, urgency, and
benefit, and their prognosticators (first step) are listed in
Appendix 3. Given their relevance to the discussion, the
statements concerning transplant benefit are also listed in
Table 1. Each statement is associatedwith ameasure of the
quality of the evidence and the strength of the recommen-
dation, as appropriate.
MELD exceptions were identified analytically, constructing
a priority for transplantation algorithm based on currently-
available scientific evidence. Four priority categories (P1–4)
were identified for MELD exceptions, defined as follows:
% P1:Veryhighpriority:warrantsorgansharingbymacroarea
(central-northern or central-southern Italy, each serving a
populationof20–25million) as forpatientswithMELD#30;
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% P2: High priority: organs to be shared within each
region (serving populations of 1–6 million, 4 regions
have more than one LT center), priority increasing
with time on the waiting list (extra points for time,
capping at 29);
% P3: Intermediate priority: organ sharing by region, priority
increasing with time on the waiting list (extra points for
time, capping at 29);
% P4: Low priority, organ sharing by region, priority
increasing with time on the waiting list (extra points
for time, capping at 29);
% P Multidisciplinary: Patients with particular indications
(see list in Table 2) must be attributed a P1–4 category
by a center’s multidisciplinary team (hepatologist, LT
surgeon, intensivologist) given the substantial lack of
scientific evidence for generally deciding priority. Such
multidisciplinary decisions will be submitted to the CNT.
Table 2 and Appendix 4 contain the proposed detailed list of
MELD exceptions relating to individual priorities. Appendix
5 provides a detailed list of statements referring to the
prioritization indicators for patients with MELD exceptions.
A list of pertinent comments explaining the content of each
statement in more detail, with related references, is also
provided (Appendix 5A).
A new classification (Table 3) and prioritization policy
(Table 4) were agreed for HCC patients. First, patients
were defined as transplantable (TT) or nontransplantable
(TNT). Since a common nationwide criterion for HCC patient
selection has yet to be agreed, HCC patients were defined
as TT if they satisfy a minimal posttransplant utility
requirement (50% 5-year patient survival). Centers have
to clearly and publicly state their chosen criteria, and select
HCC patients with at least a 50% chance of surviving
Table 1: Statements on transplant benefit. Quality of evidence and strength of recommendation are provided, when appropriate, according
to the CDC grade score (mettere voce bibliografica)
Quality of
evidence
Strength of
recommendation
BENEFIT STATEMENTS
Benefit
1. Transplant benefit of at least 5 years after transplantation is the best available indicator for
maximizing the life-saving potential of procured livers.
E2 R2
2. Transplant benefit should be regulated according to minimal acceptable posttransplant results
(UTILITY), and take into account the risk of dropout from the waiting list (URGENCY).
E2 R2
3. When measuring transplant benefit, the gain in life years is equivalent to the difference in the
mortality ratio of patients with or without LT. The measure of gain in life expectancy is more
understandable than the difference in mortality ratio with or without transplant.
E2
4. Most studies on transplant benefit calculation are based on waiting list populations. E2
5. However, the implementation of a national registry to sample prospective cohorts of cirrhotic
patients potentially eligible for LT based on the ITT principle is strongly recommended.
R1
6. Quality-adjusted life years (QALYs) should be included in the transplant benefit estimation as a
relevant endpoint. Cost effectiveness should also be evaluated, though neither evidence nor
data are available in the transplant benefit estimation.
E3 R3
7. Evaluation of potential harm to individuals and waiting-list populations should be included in the
transplant benefit estimation.
E2 R2
Benefit predictors
8. The predictors of transplant benefit in the cirrhotic patients are, at minimum, the following:
MELD and its variables, albumin, donor age, recipient age, previous liver transplant, diagnosis of
HCV, and portal vein thrombosis. Studies assessing predictors of transplant benefit are
warranted.
E2
9. Liver function is a predictor of transplant benefit in HCC patients. Indeed, in patients within
criteria for transplantation according to tumor features, BCLC stages seem to predict the
magnitude of transplant benefit.
E2 R2
10. Applicability of therapies as alternatives to transplantation is a predictor of transplant benefit in
HCC patients.
E2
11. Studies on transplant benefit, including hepatic function parameters and tumor characteristics,
are warranted.
E2 R2
Minimum threshold of benefit
12. A MELD score of 15 corresponds to a 5-year transplant benefit of 12 months of life gain. This
should be the minimal acceptable benefit. Excluding exceptions, the minimum listing criteria in
Italy for patients with end-stage liver disease is MELD 15.
E2 R2
BCLC, Barcelona Clinic Liver Cancer; CDC, Centers for Disease Control and Prevention; HCC, hepatocellular carcinoma; HCV, hepatitis C
virus; ITT, intention-to-treat; LT, liver transplantation; MELD, model for end-stage liver disease.
No strength of recommendation is given for caseswhere the content of the statements is accepted as evidence-based but does not prompt
any recommendations.
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5 years posttransplant. Either conventional (Milan criteria)
or extended criteria (e.g., up to 7, total tumor volume,
UCSF, a fetoprotein model) (9,14–16) may therefore be
used to characterize a tumor as TT (9,14,17). Patients thus
defined as TT were then classified using more dynamic
categories (Table 3): first presentation, early or late
recurrence, type of response to bridging therapy, success-
ful downstaging.
Then HCC patients were grouped into 3 priority strata,
based mainly on transplant benefit, but the risk of dropout
(urgency) and patients’ and/or physicians’ expectations
were also considered (18) (Table 3).
Patients’ position within each priority stratum would be
based on the only currently-available benefit prognosticator
(‘‘HCC-MELD’’) (19), and an agreed definition of disease
progression (Table 4).
Table 4 summarizes the whole prioritization process,
including super-urgent cases, MELD patients, MELD
exceptions, and HCC patients, all prioritized according to
the same incremental numerical scoring system.
The MELD 30 cutoff (based on the decile of the most
severe patients transplanted in 2011) for distinguishing
between macro area and regional allocations remained
unchanged for the sake of simplicity, but will be revised in
future, based on the decile of the most severe patients
transplanted in 2015.
Capping extra points for P2–4 and HCC at 29 aimed to avoid
any influence of MELD exceptions and low MELD HCC on
urgent patients. P1 and MELD >30 patients deserve the
highest possible priority (after super-urgent cases) by
macro area due to their inherent high risk of death. In
future, this capping will be reevaluated and potentially
down-modulated if it will reveal a priority unbalance favoring
MELD exceptions and/or low MELD HCCs at the expense
of biochemical MELD patients.
There is also a plan to adapt the system from MELD to
MELD-Na in the future.
Discussion
Organ allocation for LT is evolving in various parts of the
world (20–24). For instance, European transplant organiza-
tions basing their liver allocation criteria on blood group,
recipient size, clinical urgency, and time on the waiting list
reportedly revised their rules 13 times between 2006 and
2013 (20). The OPTN/UNOS is currently considering a new
liver distribution format in the US to reduce variability in
access to LT, that would divide the country geographically
into 4 or 8 districts (21). The latest UK policy changes were
Table 2: Agreed priority strata for MELD exceptions and corresponding organ-sharing areas
Priority and sharing LT indication
P1 (Macro area sharing after serving those with
MELD>30)!
Rendu–Osler–Weber
Hepatoblastoma (young adult)
Hemangioma (if Kasabach Merritt syndrome)
Acute late ReLT
FAP (if domino)
P2 (Sharing at regional level) Hepato-pulmonary syndrome
PPH
Refractory hydrothorax
Chronic late ReLT
Hepato-renal syndrome (if not automatically equated to MELD)
Previous severe infections
P3 (Sharing at regional level) Refractory ascites
FAP
Wilson’s (with compensated cirrhosis and initial neurological symptoms)
NET metastases
Hemangioendotheliomas
P4 (Sharing at regional level) PSC or PBC with intractable pruritus
Polycystic disease
Complicated adenoma
Hemangiomas
P Multidisciplinary (Center-based) Hepatic encephalopathy
Fibrolamellar HCC
Liver adenomatosis (not complicated)
Hilar cholangiocarcinoma
CRC metastases
CRC, colorectal cancer; FAP, familial amyloidotic polyneuropathy; HCC, hepatocellular carcinoma; LT, liver transplantation;MELD,model for
end-stage liver disease; NET, neuroendocrine tumours; PBC, primary biliary cirrhosis; PPH, portopulmonary hypertension; PSC, primary
sclerosing cholangitis.
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approved by the Transplant Policy Review Committee in
March 2014 (22). Many other countries, mainly in Asia, with
relatively recent experience of cadaveric organ donation are
now faced with the complexity of organ allocation, and are
developing de novo algorithms for this purpose.
The methods used to establish organ allocation policies
vary, but usually involve an organ-specific advisory board
(e.g., the Liver Advisory Group for the NHSBT in the UK, or
EUROTX in continental Europe). In some national transplant
experiences (e.g., OPTN/UNOS in the USA), major changes
to organ allocation policy are first circulated as ‘‘concept
documents’’ to receive valuable input from all interested
parties. Resulting proposals are then submitted to the
public for further comment before final decisions are
made (23).
The consensus conferences described here made it clear
that Italy’s existing allocation policy needed adapting to the
diversity of patients on the waiting list with similar MELD
scores, because there was evidence of some subgroups
being at a disadvantage, and of regional inequities.
Our consensus conference process began with a critical
review of the scientific evidence,with contributions from all
players in the system. This generated a shared awareness
and understanding of the problems, available solutions, and
their pros and cons. Careful attention was paid to the
outcomemeasures to consider in the LT setting in the light
of recent evidence and experience (first step).
The introduction of the MELD score in 2002 (25) vastly
improved the objectivity, transparency, and efficiency of
organ allocation and patient prioritization for LT, but a far
fromnegligible number of patients—includingHCCpatients
with compensated cirrhosis, and MELD exceptions—are
still prioritized using arbitrary national or regional ap-
proaches. The equity and efficiency of many international
allocation models have been questioned, particularly
concerning their endpoints (urgency vs. utility). Imbalances
in the likelihood of patients with different etiologies on the
same waiting list receiving a transplant have emerged and
prompted policy adjustments.
In our discussions on outcome measures (first step)
emerged that separately applying utility and urgency
principles without an integrated approach to allocation
and prioritization policy has several drawbacks. A broader
‘‘blended principle model’’ including the transplant benefit
conceptmight strike a better balance between urgency and
Table 4: Proposed and agreed national waiting list prioritization policies and geographical distribution of organ allocation for patients with or
without HCC and those considered MELD exceptions.
Priority PTS Category Points
Allocation
area
Super-Urgent FHF, early reLT (first come, first served) Nationwide
Urgent MELD >30 Biochemical MELD Macro area
Urgent EXCEPTIONS P1 30 Macro area
Standard EXCEPTIONS P2 25þ1/month Region
Standard Bioch MELD 15–29 Biochemical MELD Region
Standard
HCC
Stratum 1
HCC: TTDR-TTPR (downstaged patients
or partial responders to bridge
therapies)
HCC-MELD[19]þextra points for time or MELD 22 at
entryþextra points for time (at regional board’s discretion)§
Cap at 29
Region
Standard
HCC
Stratum 2
HCC: TTFR (first presentation or late
recurrence)
HCC-MELD[19]
Criteria for awarding extra points for longer waits and priority class
migration on disease progression will be set regionally (regional
board approval)#
Region
Standard
HCC
Stratum 3
HCC: T0C–T1-T0L (complete
responders or T1 tumors)
Biochemical MELD Region
Standard EXCEPTIONS P3 20þ1 every 2 months Region
Standard EXCEPTIONS P4 15þ1 every 2 months Region
FAP, familial amyloidotic polyneuropathy; FHF, fulminant hepatic failure; HCC, hepatocellular carcinoma; LT, liver transplantation; MELD,
model for end-stage liver disease; NET, neuroendocrine tumours; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis.
§Choice between ‘‘HCC MELDþextra points for longer waits’’ or ‘‘22 points at entryþextra points for longer waits’’ will be decided on a
regional basis.
#Points for disease progressionwhile on thewaiting list can be discussed and adjusted (fast vs. slow pace) according to pattern of response
or progression within the transplantability criteria. Progression has to be assessed after optimal treatments within defined protocols.
P1¼Rendu–Osler–Weber, young adult hepatoblastoma, Kasabach–Merritt, late ‘‘acute’’ retransplant.
P2¼Hepato-pulmonary syndrome, porto-pulmonary hypertension, late ‘‘chronic’’ retransplant, refractory hydrothorax, hepatorenal
syndrome, previous severe infections.
P3¼Refractory ascites, FAP, Wilson’s with initial neurological symptoms and well-compensated cirrhosis, NET metastases,
hemangioendothelioma.
P4¼Complicated adenomatosis, polycystic disease, PSC or PBC with intractable pruritus.
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posttransplant utility in the LT setting (10,12). In fact,
transplant benefit—adjusted for a minimal accepted post-
transplant utility—resulted from our national debate as an
outcome measure well worth testing with a view to
improving equity for different etiologies, and the LT
system’s efficiency at both individual and population
level (1,26–28) (Table 1).
The consensus reached at our final meeting (in February
2015, third step) was consequently that—while awaiting
more robust transplant benefit prognosticators—our organ
allocation system should reflect an appropriate combination
of the three principles (urgency, utility, and benefit) consis-
tent with the fundamental statement from Persad et al. (29):
‘‘To achieve a just allocation of scarcemedical interventions,
society must embrace the challenge of implementing a
coherent multiprinciple framework rather than relying on
simple principles or retreating to the status quo.’’
A ‘‘pure urgency’’ endpoint was identified for patients at
high risk of death in the short term (super-urgent cases,
MELD #30 and P1 exceptions) who should access a broad
geographical organ allocation area (nationwide or macro
area). P2 patients should also be granted extra points
because of their high risk of death.
The other two endpoints, ‘‘benefit’’ and ‘‘pure posttrans-
plant utility,’’ could be better managed with a regional
allocation procedure, offering the advantages of easier
donor-recipient matching and greater flexibility.
Under the unifying ‘‘blended principle concept,’’ and in the
areas of benefit and posttransplant utility, other MELD
exceptions—including complications of cirrhosis, rare liver
diseases or unusual presentations, and liver tumors—were
discussed at our second consensus conference (second
step). It was proposed an arbitrary approach to prioritizing
MELD exceptions that met with broad approval: the aim
was to focus more on a benefit principle, whenever
possible and appropriate, whereas priority had been
regulated by urgency or utility in many other cases.
The equation between MELD cases and exceptions was
also arbitrary, dividing scores from 15 to 30 into quartiles,
and equating each P category to the lowestMELD score for
the corresponding quartile (e.g., P4¼MELD 15) (30). Extra
points for time on thewaiting list were calculated according
to themeanwaiting time for patients stratified by disease in
2014. Patients with the same score would be served in
order of their time on the waiting list.
For HCC patients, the difference between expected
survival after transplantation versus any alternative thera-
pies is crucial. Accurate benefit prognosticators are lacking,
so the feasibility of other treatments, response to therapy,
and successful downstaging were considered as surro-
gates (17,31,32). It was agreed that the benefit for patients
with very early HCC in compensated cirrhosis, or HCC
patients with other radical therapeutic options (such as liver
resection) is intrinsically too low to warrant their prioritiza-
tion for transplantation, whereas impaired liver function in
HCC patients substantially increases the potential trans-
plant benefit because it limits the alternative treatment
options (5). Avenues for successfully prioritizing down-
stagedHCC patients can follow a similar logic, providing the
benefit achievable with LT is ‘‘capped’’ by a minimal
accepted posttransplant utility (predicted long-term survival
after transplantation of at least 50% at 5 years (see
statement 6, Appendix 3). These considerations led to HCC
patients being grouped into three strata, as shown in
Table 4.
Despite numerous important limitations, the HCC–MELD
system (19) was used to prioritize patients within the same
HCC stratum because it is the only published score
that strikes a balance between HCC and non-HCC patients,
and considers benefit as an endpoint. The score gives
considerable weight to the severity of liver function
impairment as an indication of the inapplicability of
alternative therapies, and reflects the negative impact of
a-fetoprotein on posttransplant prognosis. The system still
needs prospective validation, however (7,26,27).
Due to an intrinsically greater benefit of LT, patients in HCC
stratum 1 (TTDR, TTPR) could be given higher priority by
adding more extra points to their HCC MELD score than in
the other HCC strata (TTFR).
Our open debate clearly revealed, however, that consider-
ing transplant benefit as a major outcome measure has
important drawbacks. Prognostic benefit models are still
relatively inaccurate, and little is known about benefit
predictors in certain numerically relevant indications for LT,
such as HCC and MELD exceptions.
An allocation policy focusing exclusively on transplant
benefit might also intrinsically favor patients with underly-
ing diseases associated with a better posttransplant
prognosis (e.g., PBC), and younger patients (1,12). Such
equity imbalances could be partially adjusted by choosing
an appropriate time horizon for transplant benefit (e.g.,
10 years after LT). Ethical issues will play a relevant part in
any such adjustments.
As a final step, our group tested the weight of the main
organ allocation principles on the nationwide distribution of
liver resources in 2014 (see Figure 1). This somewhat
general and arbitrary graphic representation can serve as a
benchmark in future national or international comparisons
for optimizing the balance between the different principles,
and guiding future resource investments. It was agreed, for
instance, that transplant centers should adopt a ‘‘pure
posttransplant utility’’ policy to allocate no more than 40%
of their next year’s overall donor resources and this
proportion should be adjusted annually in the light of
epidemiological studies and waiting list dropout data.
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It was also agreed that up to 5% of the country’s liver
resources be used in innovative, multicenter studies and a
crucial commitment was made to conduct prospective
studies on benefit prognosticators (particularly for HCC
patients) for validating benefit-oriented allocation models.
This report has a contribution to offer the transplant
community partly because it comes 9 years after the
International Consensus on MELD Exception was pub-
lished in Liver Transplantation in 2006 (3). Another
interesting consensus conference report dedicated specifi-
cally to HCC was published a few years ago (33) and was
widely appreciated, the outcome becoming a reference for
most LT centers around the world. No other equally
thorough and detailed consensus conference reports on LT
have been published since.
In conclusion, our multistep consensus-based procedure is
a potentially effective solution for dealing with the complex
issue of liver allocation, with its conflicting principles,
diverging endpoints, and different clinical disease presen-
tations. It generated a ‘‘blended principlemodel’’ in which a
weighted, dynamic, and verifiable balance of different
organ allocation principles was judged the best solution.
We hope our Italian experience will stimulate further
discussion in the international transplant community,
both in countries where LT is already well established,
and in those where the deceased donor transplant process
is still being developed.
I-BELT (Italian Board of Experts in the Field
of Liver Transplantation)
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Figure 1: Ideogram of donor resource distribution among the main liver allocation principles in Italy. Location of the different
diseases in the urgency, benefit, or utility principles is for guidance only, intended to reflect the dominant principle, with a marked potential
for overlaps. Multidisc: arbitrary multidisciplinary decision on priority for unconventional indications. PREVAL 2014: prevalence of national
guidelines for transplantation in 2014 stratified by main allocation principle. FUTURE AIM: nationwide agreement on resource distribution
goals for the next 3 years. HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease.
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